Eli Lil­ly's Covid-19 part­ner Ab­Cellera pays $90M for some very spe­cial mice as Pe­ter Thiel jumps on the board and IPO ru­mors heat up

Ab­Cellera Bi­o­log­ics is step­ping on­to Re­gen­eron’s turf, putting down $90 mil­lion in cash to buy out Tri­an­ni and its hu­man­ized mouse tech­nol­o­gy for de­vel­op­ing an­ti­bod­ies.

The 7-year-old biotech out of British Co­lum­bia is af­ter the Tri­an­ni Mouse: a ge­net­i­cal­ly en­gi­neered ro­dent that can gen­er­ate ful­ly hu­man mon­o­clon­al an­ti­bod­ies. It’s al­so scoop­ing up sev­er­al “next-gen­er­a­tion” mice un­der de­vel­op­ment. The move comes as Ab­Cellera preps one of the biggest IPOs in an al­ready record-break­ing year for pub­lic de­buts, un­named sources told Bloomberg. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER